Aclarion adds UHealth, University of Miami as trial site for Nociscan

Aclarion (ACON) announced the addition of UHealth – University of Miami Health System and the University of Miami Miler School of Medicine as a CLARITY – Chronic Low bAck pain Randomized Independent Trial studY – trial site. The CLARITY study is designed to demonstrate Nociscan’s clinical and economic value in spine surgery. UHealth in conjunction with the Miller School of Medicine, is the latest CLARITY trial site, joining Johns Hopkins Medicine, Northwestern Medicine, Advocate Aurora Research Institute, Texas Back Institute, and Keck Medicine at USC. The CLARITY trial will enroll 300 patients at multiple high-volume sites across the US. The primary endpoint is change in back pain as measured on a 100mm VAS Back at 12 months compared to baseline, with several secondary endpoints collected.